What is Changing: 

  • Implementation Extended to January 31, 2025: Effective January 31, 2025, Gilead’s Patient Assistance Programs (PAPs), including Advancing Access, will stop providing free medications for medicines where there are multisource generics or low program utilization. This includes TRUVADA®, EMTRIVA®, TYBOST® and COMPLERA®. Similarly, our PAPs will stop providing free medications for the non-HIV-related medicines, SOVALDI® and ZYDELIG®, due to the broad generic availability or low utilization of these medicines. Eligible enrollees will continue to receive medications free of charge until January 31, 2025, and new enrollments in the program may continue until one month prior to the program end (December 31, 2024), which allows transition time for the programs.
  • Exception for Individuals Assigned Female at Birth through July 31, 2025: We will create an exception process for up to six months for individuals assigned female at birth prescribed Truvada for HIV prevention who have affordability challenges with generic FTC/TDF. Individuals assigned female at birth may receive notifications of termination since our free drug program does not currently distinguish gender as eligibility criteria. However, through an exceptions process, eligible individuals assigned female at birth can call Advancing Access and request an exception. For these eligible individuals, the Truvada free drug program will end on July 31, 2025, and that will be the last day to both receive free product and to enroll in the program.

What is NOT Changing: 

  • All of Gilead’s other patient support offerings through programs like Advancing Access remain available for individuals regardless of whether or not they receive free medicines from Gilead. This includes general coverage inquiries, benefits investigation requests, alternate coverage assessments, and co-pay coupon support for commercially insured, eligible individuals for TRUVADA®, EMTRIVA®, TYBOST® and COMPLERA®.
  • Gilead will continue to provide free HIV prevention and HIV treatment medications for eligible individuals through Advancing Access, including BIKTARVY®, DESCOVY®, GENVOYA®, ODEFSEY®, STRIBILD® and SUNLENCA®.

Our Notification Timeline  

Our notification timelines are still being finalized internally and we ask that you keep this information confidential. At this time, we plan to stagger the notifications, currently planned for:

  • October 1: Notifications to select, highly impacted facilities, relevant state agencies (e.g., departments of health via their representative bodies NASTAD and NCSD) and community partners.
  • October 8: Notifications to all healthcare providers with impacted individuals.
  • October 15: Notifications to all impacted individuals.